Results 41 to 50 of about 6,309 (194)

Protein-Remodeling Factors As Potential Therapeutics for Neurodegenerative Disease [PDF]

, 2017
Protein misfolding is implicated in numerous neurodegenerative disorders including amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, and Huntington's disease.
James Shorter, Meredith E. Jackrel
core   +1 more source

Cardiac Biomarker Change at 1 Year After Tafamidis Treatment and Clinical Outcomes in Patients With Transthyretin Amyloid Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Although tafamidis treatment improves prognosis in patients with wild‐type transthyretin amyloid cardiomyopathy, an optimal surrogate marker monitoring its therapeutic effect remains unclear.
Naoto Kuyama, Seiji Takashio, Tetsuya Oguni, Masahiro Yamamoto, Kyoko Hirakawa, Masanobu Ishii, Shinsuke Hanatani, Seitaro Oda, Yasushi Matsuzawa, Hiroki Usuku, Eiichiro Yamamoto, Toshinori Hirai, Mitsuharu Ueda, Kenichi Tsujita   +13 more
doaj   +1 more source

Urinary Biomarkers for Kidney Disease in ATTR Amyloidosis [PDF]

, 2014
Aim: The detection and prognosis of nephropathy in transthyretin amyloidosis depends on albuminuria and renal function. Knowing that urinary levels of alpha-1 microglobulin and beta-2 microglobulin reflect tubular dysfunction while urinary alpha-2 ...
Beirão, I., Bravo, F., Lobato, L., Oliveira, J., Rocha, A., Vizcaíno, J.   +5 more
core   +1 more source

Diflunisal versus tafamidis on neuropathy and cardiomyopathy in hereditary transthyretin amyloidosis

Annals of Clinical and Translational Neurology
Objectives Hereditary transthyretin (TTR) amyloidosis (ATTRv) is frequently complicated by polyneuropathy (ATTRv‐PN) and cardiomyopathy (ATTRv‐CM).
Chi‐Chao Chao, Shiou‐Ru Tzeng, Ming‐Chang Chiang, Hsueh‐Wen Hsueh, Wan‐Jen Hsieh, Yuan‐Chun Chao, Mei‐Fang Cheng, Yen‐Hung Lin, Mao‐Yuan Su, Chun‐Hsiang Huang, Yi‐Shiang Wang, Ming‐Fang Hsieh, Ping‐Huei Tseng, Sung‐Tsang Hsieh   +13 more
doaj   +1 more source

Modern approaches to cardiovascular amyloidosis treatment

Russian Open Medical Journal, 2021
Cardiovascular (cardiac) amyloidosis (CA) is a clinical pathology, usually of a geneticallymediated nature, initiated by the precipitation process of the insoluble fibrous protein with β-pleated sheet secondary structure.
Svetlana N. Morozkina, Petr P. Snetkov, Roman O. Olekhnovich, Mayya V. Uspenskaya   +3 more
doaj   +1 more source

Mid- and long-term anxiety levels associated with presymptomatic testing of Huntington's disease, Machado-Joseph disease, and familial amyloid polyneuropathy [PDF]

, 2016
http://sherpa.ac.uk/romeo/search.php?issn=1809-452XOBJECTIVE: To study anxiety as a variable of the mid- and long-term psychological impact of pre-symptomatic testing for three autosomal dominant late-onset disorders - Huntington's disease (HD), Machado ...
Dinis, Maria Alzira Pimenta, Leite, Ângela, Lêdo, Susana, Sequeiros, Jorge, Souto, Teresa   +4 more
core   +3 more sources

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Eficacia y costo-efectividad de tafamidis para el tratamiento de la cardiopatía por amiloidosis transtirretina

Revista Colombiana de Cardiología
Introducción: El uso de tafamidis ha sido aprobado para el manejo de la miocardiopatía por amilodosis transtirretina (CM-ATTR). Sin embargo, su alto costo obliga a evaluar su eficacia y costoefectividad.
Juan C. Díaz, Julián M. Aristizábal, Oriana Bastidas, Jorge E. Marín, César D. Niño, Mauricio Duque   +5 more
doaj   +1 more source

Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial [PDF]

, 2018
Background: Hereditary transthyretin (ATTRm) amyloidosis is a rare, progressive and fatal disease with a range of clinical manifestations.Objective: This study comprehensively evaluates disease characteristics in a large, diverse cohort of patients with ...
Ackermann, Elizabeth J., Barroso, Fabio A., Benson, Merrill D., Berk, John L., Coelho, Teresa, Dyck, P. James B., Dyck, Peter J., Gertz, Morie A., Heitner, Stephen B., Hughes, Steven G., Jung, Shiangtung W., Kwoh, T. Jesse, Monia, Brett P., Polydefkis, Michael, Tai, Li, Waddington-Cruz, Marcia, Wang, Annabel K.   +16 more
core   +3 more sources

Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 1176-1182, April 2025.
Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy, G. Giblin, A. Gray, N. Starr, L. Murphy, D. O'Sullivan, E. Kavanagh, C. Howley, C. Tracey, E. Morrin, A. McDaid, A. Clarke, J.O. O'Neill, E. Joyce, M. O'Connell, N. G. Mahon   +15 more
wiley   +1 more source